Title: Unraveling PINK1 regulation: Ubiquitination of its mature form and insights for Parkinson's disease
Abstract: Movement DisordersVolume 32, Issue 11 p. 1546-1546 Hot Topics Unraveling PINK1 regulation: Ubiquitination of its mature form and insights for Parkinson's disease Usman Saeed MSc candidate, Usman Saeed MSc candidate orcid.org/0000-0001-7149-8406 Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorMario Masellis MD, PhD, Corresponding Author Mario Masellis MD, PhD [email protected] Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada Cognitive & Movement Disorders Clinic; Hurvitz Brain Sciences Research Program; Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, CanadaCorrespondence to: Dr. Mario Masellis, 2075 Bayview Ave., Room A4-55, Toronto, Ontario, Canada M4N 3M5; [email protected] for more papers by this author Usman Saeed MSc candidate, Usman Saeed MSc candidate orcid.org/0000-0001-7149-8406 Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorMario Masellis MD, PhD, Corresponding Author Mario Masellis MD, PhD [email protected] Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada Cognitive & Movement Disorders Clinic; Hurvitz Brain Sciences Research Program; Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, CanadaCorrespondence to: Dr. Mario Masellis, 2075 Bayview Ave., Room A4-55, Toronto, Ontario, Canada M4N 3M5; [email protected] for more papers by this author First published: 04 October 2017 https://doi.org/10.1002/mds.27171 Relevant conflicts of interest/financial disclosures: : Usman Saeed is supported by the Ontario Graduate Scholarship, University of Toronto. Mario Masellis has served as an adviser to Bioscape Medical Imaging CRO, Novartis, and UCB; received honoraria from Novartis; received royalties from Henry Stewart Talks Ltd.; received an investigator-initiated research grant from Teva; received contract research support from Roche Novartis and Axovant; received peer-reviewed research support from the Canadian Institutes of Health Research, Ministry of Research, Science, and Innovation (Ontario), Weston Brain Institute, Sunnybrook AFP Innovation Fund, Washington University, Parkinson Society Canada, Alzheimer's Drug Discovery Foundation, Brain Canada, and Ontario Brain Institute; Early Research Award, Ministry of Research, Innovation, and Science (MRIS), Ontario; and received salary support from the Department of Medicine at Sunnybrook Health Sciences Centre and University of Toronto, and from the Sunnybrook Foundation. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume32, Issue11November 2017Pages 1546-1546 RelatedInformation
Publication Year: 2017
Publication Date: 2017-10-04
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot